Latham & Watkins LLP represented Senda Biosciences in the transaction.
Senda Biosciences, a therapeutics platform company creating novel categories of medicines based on a new field of science called Intersystems Biology, has entered into a strategic collaboration with Nestlé Health Science for the development of novel nutritional therapies for a wide range of metabolic conditions, including obesity and glycemia.
Latham & Watkins LLP represented Senda Biosciences in the transaction. The strategic collaboration was led by partner Judith Hasko (Picture), with associates Jekkie Kim and Seth Appiah-Opoku. Corporate aspects of the transaction were led by partner Peter Handrinos, with associate Samuel Niles. Advice was also provided on tax matters by partner Kirt Switzer, with associate Derek Berry; and on regulatory matters by partner Ben Haas.
Involved fees earner: Seth Appiah-Opoku – Latham & Watkins; Derek Berry – Latham & Watkins; Ben Haas – Latham & Watkins; Peter Handrinos – Latham & Watkins; Judith Hasko – Latham & Watkins; Jekkie Kim – Latham & Watkins; Samuel Niles – Latham & Watkins; Kirt Switzer – Latham & Watkins;
Law Firms: Latham & Watkins;
Clients: Senda Biosciences;